Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #ASCO--Opdivo in Combination with CABOMETYX Demonstrates Continued Survival Benefits

Click to view original post